Evidence map›Paper›PMID 42133146›Full record

ArticleMolecular biology reports2026

Piperlongumine inhibits the proliferation and migration of non-small cell lung cancer cells through the EGFR/FAK/STAT3 pathway.

Qianwen Huang, Wen Chen, Xin Xu, Jiaxin Hua, Lehui Li, Ping Hu, Wei Zhang, Longhua Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qianwen HuangThe Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, People's Republic Of China.
Wen ChenThe Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, People's Republic Of China.
Xin XuThe Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, People's Republic Of China.
Jiaxin HuaInstitute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, 330031, Jiangxi, People's Republic Of China.
Lehui LiInstitute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, 330031, Jiangxi, People's Republic Of China.
Ping HuJiangxi Provincial Key Laboratory of Respiratory Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, People's Republic Of China.
Wei ZhangThe Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, People's Republic Of China. zhangweiliuxin@163.com.
Longhua SunThe Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, People's Republic Of China. ndyfy05715@ncu.edu.cn.

Funding

National Natural Science Foundation of China No.82360474
6 · The paper itself

Abstract

purposeLung cancer remains the predominant cause of cancer-related mortality worldwide. Piperlongumine is a natural extract that has antitumor effects. However, the mechanism of Piperlongumine on lung cancer remains to be elucidated. This study aimed to investigate the effects and potential mechanisms of Piperlongumine on non-small cell lung cancer.

methodsThe anti-proliferative ability of Piperlongumine on lung cancer was assessed using the Cell Counting Kit-8 (CCK-8) and colony formation assays. The cell migration ability was evaluated by the wound healing assay. Additionally, western blot and immunofluorescence assays were performed to examine the expression levels of relevant proteins.

resultsOur results indicated that Piperlongumine effectively inhibited the proliferation and migration of A549 and H1299 cells. Mechanistically, Piperlongumine suppressed the phosphorylation of epidermal growth factor receptor (EGFR), focal adhesion kinase (FAK), and signal transducer and activator of transcription 3 (STAT3). It also blocked EGF-induced phosphorylation of FAK and STAT3, as well as EGF-induced cell proliferation. Furthermore, Piperlongumine reduced the expression of Cyclin D1.

conclusionsPiperlongumine inhibits lung cancer cell proliferation and migration by modulating the EGFR/FAK/STAT3 signaling pathway. These findings suggest that Piperlongumine may serve as a potential drug for the treatment of lung cancer.

Indexed as

Carcinoma, Non-Small-Cell LungDioxolanesLung NeoplasmsA549 CellsCell Line, TumorCell MovementCell ProliferationErbB ReceptorsFocal Adhesion Kinase 1HumansPhosphorylationPiperidonesSignal TransductionSTAT3 Transcription FactorDioxolanesEGFR protein, humanErbB ReceptorsFocal Adhesion Kinase 1PiperidonespiperlonguminePTK2 protein, humanSTAT3 protein, humanSTAT3 Transcription FactorEGFR/FAK/STAT3 pathwayLung cancerMigrationPiperlongumineProliferation

Identifiers

PMID42133146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.